CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

Author:

Shadman Mazyar1,Gopal Ajay K.2,Smith Stephen D.3,Lynch Ryan C.3,Ujjani Chaitra S.3,Turtle Cameron J.4,Greenbaum Adam5,Redman Mary5,Yeung Cecilia4,Sersch Martina6,Warren Edus H.4,Maloney David G.5,Till Brian G.4

Affiliation:

1. Uw/Fred Hutchinson Cancer Research Center, Seattle, WA

2. Seattle Cancer Care Alliance, Seattle, WA

3. University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

5. Fred Hutchinson Cancer Research Center, Seattle, WA

6. Mustang Bio, Inc., New York, NY

Abstract

Background: Chimeric antigen receptor T-cells (CAR-T) targeting CD19 have shown clinical efficacy in high-risk B-cell lymphomas, which has led to approval of 2 such therapies (axicabtagene ciloleucel and tisagenlecleucel) for large B-cell lymphoma after 2 lines of treatment. Despite the promising results, complete remission (CR) is achieved in ~ 50% of patients, and with longer follow-up progression-free survival is around 40%. Therefore, finding effective treatments for high-risk B-NHLs remains an unmet need. CD20 is a proven therapeutic target for B-Cell Non-Hodgkin Lymphomas (B-NHL), supported by previously approved naked and radiolabeled anti-CD20 monoclonal antibodies and a number of studies investigating novel bispecific antibodies targeting this antigen. CD20-targeted CAR-T is another potential adoptive immunotherapy option that could be utilized in combination or sequentially before or after CD19 CAR-T, depending on efficacy. Here, we present our ongoing phase I/II clinical trial investigating safety and efficacy of CD20 CAR-T for high-risk B-NHLs (NCT03277729). Methods: MB-106 is a fully human third-generation CD20 targeted CAR-T with both 4-1BB and CD28 costimulatory domains. In the phase I portion of the study we use a continual reassessment method dose escalation design to find the maximally tolerated dose. Lymphodepletion (LD) chemotherapy consists of fludarabine and cyclophosphamide. Patients (pts) will undergo a mandatory biopsy before LD to confirm the diagnosis and CD20 expression. A repeat research biopsy will be done between 10-16 days after CAR-T infusion (Figure 1). Except for the first patient of each dose cohort, treatment is given in the outpatient setting (Fred Hutch/Seattle Cancer Care Alliance) and pts will only be admitted to the University of Washington Medical Center if clinically indicated after CAR-T infusion. Response to treatment will be assessed on day 28 using Lugano criteria. Patients with relapsed or refractory CD20 positive B-NHL are eligible, including but not limited to DLBCL, primary mediastinal lymphoma, follicular lymphoma or other indolent histologies, and mantle cell lymphoma. Prior treatment with CD19 CAR-T is permitted as long as there is evidence of B-cell recovery in peripheral blood (≥ 20 B cells/µl) as a functional test to rule out persistent CD19 CAR-Ts. Patients need to meet standard organ function criteria and have adequate blood counts (ANC >750, Hb >8.5, Plts >50,000). Patients with significant neurologic conditions, active CNS lymphoma, or need for systemic immunosuppressive therapy are excluded from the study. Disclosures Shadman: Mustang Bio: Research Funding; Verastem: Consultancy; Genentech: Consultancy, Research Funding; Atara Biotherapeutics: Consultancy; Pharmacyclics: Consultancy, Research Funding; ADC Therapeutics: Consultancy; Celgene: Research Funding; Sound Biologics: Consultancy; TG Therapeutic: Research Funding; Acerta Pharma: Research Funding; Sunesis: Research Funding; Gilead: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; BeiGene: Research Funding; Astra Zeneca: Consultancy. Gopal:Seattle Genetics, Pfizer, Janssen, Gilead, Sanofi, Spectrum, Amgen, Aptevo, BRIM bio, Acerta, I-Mab-pharma, Takeda, Compliment, Asana Bio, and Incyte: Honoraria; Seattle Genetics, Pfizer, Janssen, Gilead, Sanofi, Spectrum, Amgen, Aptevo, BRIM bio, Acerta, I-Mab-pharma, Takeda, Compliment, Asana Bio, and Incyte.: Consultancy; Teva, Bristol-Myers Squibb, Merck, Takeda, Seattle Genetics, Pfizer, Janssen, Takeda, and Effector: Research Funding. Smith:Pharmacyclics: Research Funding; Genentech: Research Funding; Ignyta (spouse): Research Funding; Portola Pharmaceuticals: Research Funding; Bristol-Myers Squibb (spouse): Research Funding; Ayala (spouse): Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding; Acerta Pharma BV: Research Funding; Merck Sharp & Dohme Corp: Consultancy, Research Funding; Incyte Corporation: Research Funding; Seattle Genetics: Research Funding; Denovo Biopharma: Research Funding. Lynch:Juno Therapeutics: Research Funding; Rhizen Pharmaceuticals S.A: Research Funding; Takeda Pharmaceuticals: Research Funding; Johnson Graffe Keay Moniz & Wick LLP: Consultancy; Incyte Corporation: Research Funding; T.G. Therapeutics: Research Funding. Ujjani:Pharmacyclics: Honoraria; PCYC: Research Funding; Gilead: Consultancy; Astrazeneca: Consultancy; Atara: Consultancy; Genentech: Honoraria; AbbVie: Honoraria, Research Funding. Turtle:T-CURX: Membership on an entity's Board of Directors or advisory committees; Humanigen: Other: Ad hoc advisory board member; Eureka Therapeutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Precision Biosciences: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Caribou Biosciences: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Allogene: Other: Ad hoc advisory board member; Juno Therapeutics: Patents & Royalties: Co-inventor with staff from Juno Therapeutics; pending, Research Funding; Nektar Therapeutics: Other: Ad hoc advisory board member, Research Funding; Kite/Gilead: Other: Ad hoc advisory board member; Novartis: Other: Ad hoc advisory board member. Yeung:Pfizer: Research Funding; OBI Pharmaceutical: Research Funding; Merck: Consultancy; DiaCarta: Consultancy. Sersch:Mustang Bio: Employment. Maloney:Juno Therapeutics: Honoraria, Patents & Royalties: patients pending , Research Funding; Celgene,Kite Pharma: Honoraria, Research Funding; BioLine RX, Gilead,Genentech,Novartis: Honoraria; A2 Biotherapeutics: Honoraria, Other: Stock options . Till:Mustang Bio: Patents & Royalties, Research Funding.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3